- Q4 & FY 2025 Revenue Growth: Total revenue reached $1.57B for Q4 and $5.93B for FY 2025, reflecting steady growth but with elevated cost trends (7.5% in 2026 vs. 6.5% in 2025).
- Medical Margin & EBITDA Turnaround: Full-year 2025 medical margin of -$57M and adjusted EBITDA of -$296M, but 2026 guidance targets $325M medical margin and breakeven EBITDA, driven by disciplined contracting and cost reductions.
- Operational Cost Cuts: $35M in operating cost reductions achieved in 2025, with G&A expenses projected at $234M in 2026, slightly below 2025 levels.
- ACO REACH Contribution: Expected $20–25M to 2026 adjusted EBITDA from ACO REACH, alongside 103,000 ACO members and 7% membership in Special Needs Plans.
- Liquidity & Strategic Positioning: Ended Q4 with $285M in cash and secured credit facility extensions, planning a reverse stock split and $15M geo expansion expenses for FY 2026.
Guidance and Outlook
For 2026, Agilon Health expects revenue of $5.5 billion, a medical margin of $325 million, and adjusted EBITDA at breakeven. The company anticipates membership to be around 430,000 in Medicare Advantage and 103,000 in ACO models. The guidance assumes a gross cost trend of 7.5% for 2026 and a net 40 basis point improvement year-over-year in risk-based revenue. The expected medical margin reflects disciplined contracting efforts and a conservative cost trend assumption.
Transformation Initiatives
Agilon Health made progress in its transformation initiatives, including a disciplined approach to contracting, improvements in its burden of illness program, and enhancements to its clinical and quality programs. The company executed $35 million in operating cost reductions and ended the quarter with $285 million in cash and marketable securities. The company has extended its credit facility and term loan, providing a stable financial foundation.
Valuation Metrics
With a P/E Ratio of -0.62 and an EV/EBITDA of -0.24, the market is pricing in significant challenges for Agilon Health. The P/S Ratio is 0.04, indicating a low revenue multiple. The Net Debt / EBITDA ratio is 0.42, suggesting manageable debt levels relative to EBITDA. As the company navigates the challenges of elevated cost trends and risk model changes, its valuation metrics will be closely watched.
Risk Model Changes and Mitigation
Agilon Health is disappointed with the advanced rate notice released by CMS but believes its BOI and clinical pathway initiatives will help mitigate the impact of the risk model revision and normalization factor. The company feels confident in its ability to offset the implementation of V28, which was roughly 3% to 3.5% per year, and plans to do so again in 2027. The implementation of clinical pathways, particularly congestive heart failure, has driven growth, with 90% of the platform implemented in that program.